Affiliation:
1. Department of Pharmacology, Faculty of Medicine, Masaryk University Brno, Czech Republic
Abstract
Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. In addition to targeting cancer antigens antibodies can also modulate immunological pathways that are critical to immune surveillance. Antibody therapy directed against several negative immunologic regulators (checkpoints) is demonstrating significant success in the past few years. Immune checkpoint inhibitors, ipilimumab, pembrolizumab and nivolumab, have shown significant clinical benefit in several malignancies and are already approved for advanced melanoma and squamous NSCLC. Based on their mechanism of action, these agents can exert toxicities that are unlike conventional cytotoxic chemotherapy, whose nature is close to autoimmune diseases - immune related adverse events (irAEs). In this review we focus on the spectrum of irAEs associated with immune checkpoint antibodies, discussing the pharmacological treatment strategy and possible clinical impact.
Publisher
Institute of Physiology of the Czech Academy of Sciences
Subject
General Medicine,Physiology
Reference26 articles.
1. CATAPANO AL, PAPADOPOULOS N: The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 228: 18-28, 2013.
2. Datamonitor: Pipeline insight: Biologic targeted cancer therapies – Next generation jostles for market position, DMHC2573, 2009.
3. DELLA SCARPATI GV, FUSCIELLO C, PERRI F, SABBATINO F, FERRONE S, CARLOMAGNO C, PEPE S: Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 7: 203-209, 2014.
4. EDWARDS IR, ARONSON JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet 356: 1255-1259, 2000.
5. EMA (European Medicines Agency) 2012, http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf.
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献